Liver tumors: an overview
2008-05-01 Munechika Enjoji Affiliation1.Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan
Classification
Classification
WHO histological classification of the liver and intrahepatic bile ducts. Epithelial tumors Non-epithelial tumors Miscellaneous tumors Hematopoietic and lymphoid tumors Secondary tumors Epithelial abnormalities Miscellaneous lesions
- Benign:
- Hepatocellular adenoma
- Focal nodular hyperplasia
- Intrahepatic bile duct adenoma
- Intrahepatic bile duct cystadenoma
- Biliary papillomatosis
- Malignant:
- Hepatocellular carcinoma
- Intrahepatic cholangiocarcinoma
- Bile duct cystadenocarcinoma
- Combined hepatocellular and cholangiocarcinoma
- Hepatoblastoma
- Undifferentiated carcinoma
- Benign:
- Angiomyolipoma
- Lymphangioma and lymphangiomatosis
- Hemangioma
- Infantile hemangioendothelioma
- Malignant:
- Epithelioid hemangioendothelioma
- Angiosarcoma
- Embryonal sarcoma
- Rhabdomyosarcoma
- Others
- Solitary fibrous tumor
- Teratoma
- York sac tumor
- Carcinosarcoma
- Rhabdoid tumor
- Others
- Liver cell dysplasia
- Dysplastic nodules
- Bile duct abnormalities
- Mesenchymal hamartoma
- Nodular transformation
- Inflammatory pseudotumor
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 16613323 | 2006 | Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. | Aishima S et al |
| 12846405 | 2003 | Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. | Altimari A et al |
| 17651785 | 2007 | Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma. | Berg JP et al |
| 15288479 | 2004 | Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. | Cazals-Hatem D et al |
| 8129031 | 1994 | Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. | Charlotte F et al |
| 12297840 | 2002 | P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. | Chen YW et al |
| 11260864 | 2001 | Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study. | Cong WM et al |
| 17962810 | 2008 | Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations. | Curia MC et al |
| 11014564 | 2000 | Genetic classification of combined hepatocellular-cholangiocarcinoma. | Fujii H et al |
| 15566504 | 2004 | Alterations of p53, Bcl-2, and hMSH2 protein expression in the cirrhotic, macroregenerative, dysplastic nodules and hepatocellular carcinomas in Upper Egypt. | Hussein MR et al |
| 8957064 | 1996 | Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas. | Imai Y et al |
| 10212000 | 1999 | Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. | Kang YK et al |
| 11914628 | 2002 | Expression of KIT (CD117) in angiomyolipoma. | Makhlouf HR et al |
| 15588850 | 2005 | Cytogenetic abnormalities in hepatoblastoma: report of two new cases and review of the literature suggesting imbalance of chromosomal regions on chromosomes 1, 4, and 12. | Nagata T et al |
| 16397610 | 2006 | Cholangiocarcinoma. | Patel T et al |
| 8381245 | 1993 | Immunolocalization of ras oncogene p21 in human liver diseases. | Radosevich JA et al |
| 15030983 | 2004 | Multiple chromosomal abnormalities in human liver (pre)neoplasia. | Raidl M et al |
| 10389981 | 1999 | Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia. | Schlott T et al |
| 12910509 | 2003 | Where do we stand with hepatoblastoma? A review. | Schnater JM et al |
| 9864969 | 1998 | Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder. | Shrestha ML et al |
| 11034592 | 2000 | Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. | Tannapfel A et al |
| 9822921 | 1998 | c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. | Terada T et al |
| 12768875 | 2003 | Cytogenetic alterations in liver cell tumors as detected by comparative genomic hybridization. | Terracciano L et al |
| 16858537 | 2006 | Role of epigenetic alterations in cholangiocarcinoma. | Tischoff I et al |
| 11904335 | 2002 | Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. | Torbenson M et al |
| 7926462 | 1994 | Point mutation of K-ras gene codon 12 in biliary tract tumors. | Watanabe M et al |
| 9110301 | 1997 | Hepatobiliary and pancreatic mucinous cystadenocarcinomas with mesenchymal stroma: analysis of estrogen receptors/progesterone receptors and expression of tumor-associated antigens. | Weihing RR et al |
| 9365169 | 1997 | Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma. | Wu CG et al |
| 7796400 | 1995 | Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. | Yoshida S et al |
Citation
Munechika Enjoji
Liver tumors: an overview
Atlas Genet Cytogenet Oncol Haematol. 2008-05-01
Online version: http://atlasgeneticsoncology.org/solid-tumor/5273/liver-tumors-an-overview
